QID 377655

Date Published: 2022-11-14

QID 377655: F5 BIG-IP Application Security Manager (ASM) Big-ip Application Security Manager (ASM) icontrol rest Vulnerability cve-2022-41617 (K11830089)

When the F5 BIG-IP Advanced WAF or BIG-IP ASM module is provisioned, an authenticated remote code execution vulnerability exists in the BIG-IP iControl REST interface.CVE-2022-41617

Vulnerable Component: BIG-IP ASM

Affected Versions:
16.1.0 - 16.1.3
15.1.0 - 15.1.6
14.1.0 - 14.1.5
13.1.0 - 13.1.5

QID Detection Logic(Authenticated):
This QID checks for the vulnerable versions of F5 BIG-IP devices using the tmsh command.

On systems deployed in Standard or Appliance mode, this vulnerability may allow a high privileged authenticated attacker with network access to the iControl REST interface to run arbitrary system commands, create or delete files, or disable services. There is no data plane exposure; this is a control plane issue only. Appliance mode is enforced by a specific license or may be enabled or disabled for individual Virtual Clustered Multiprocessing (vCMP) guest instances. For more information about Appliance mode, refer to K12815: Overview of Appliance mode.

CVSS V3 rated as High - 7.2 severity.

CVSS V2 rated as Medium - 5.4 severity.

Solution

For more information about patch details please refer to K11830089

Vendor References

K11830089 - support.f5.com/csp/article/K11830089

CVEs related to QID 377655

CVE-2022-41617 |

Software Advisories

Advisory ID	Software	Component	Link
K11830089			support.f5.com/csp/article/K11830089

By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].